DataVXAdvanced MaterialsPaper
journal article·2018-08Open access

Dotted Core–Shell Nanoparticles for T1‐Weighted MRI of Tumors

Zheyu Shen, Jibin Song, Zijian Zhou, Bryant C. Yung, Maria A. Aronova, Yan Li, Yunlu Dai, Wenpei Fan, Yijing Liu, Zihou Li, Huimin Ruan, Richard D. Leapman, Lisen Lin, Gang Niu, Xiaoyuan Chen, Aiguo Wu

Advanced Materials· Volume 30· Issue 33
Publisher pageOpen full text
Source abstract

Abstract

Abstract Gd‐based T 1‐weighted contrast agents have dominated the magnetic resonance imaging (MRI) contrast agent market for decades. Nevertheless, they are reported to be nephrotoxic and the U.S. Food and Drug Administration has issued a general warning concerning their use. In order to reduce the risk of nephrotoxicity, the MRI performance of the Gd‐based T 1‐weighted contrast agents needs to be improved to allow a much lower dosage. In this study, novel dotted core–shell nanoparticles (FeGd‐HN3‐RGD2) with superhigh r 1 value (70.0 mM−1 s−1) and very low r 2/r 1 ratio (1.98) are developed for high‐contrast T 1‐weighted MRI of tumors. 3‐(4,5‐Dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) assay and histological analyses show good biocompatibility of FeGd‐HN3‐RGD2. Laser scanning confocal microscopy images and flow cytometry demonstrate active targeting to integrin αvβ3 positive tumors. MRI of tumors shows high tumor ΔSNR for FeGd‐HN3‐RGD2 (477 ± 44%), which is about 6‐7‐fold higher than that of Magnevist (75 ± 11%). MRI and inductively coupled plasma results further confirm that the accumulation of FeGd‐HN3‐RGD2 in tumors is higher than liver and spleen due to the RGD2 targeting and small hydrodynamic particle size (8.5 nm), and FeGd‐HN3‐RGD2 is readily cleared from the body by renal excretion.
Source: crossref · Quality: baseline

Research context

NanomaterialsBiomaterials

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Lanthanide and Transition Metal Complexes

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

CAS Key Laboratory of Magnetic Materials and Devices Key Laboratory of Additive Manufacturing Materials of Zhejiang Province Division of Functional Materials and Nanodevices Ningbo Institute of Materials Technology and Engineering Chinese Academy of Sciences 1219 Zhong‐guan West Road Ning‐bo Zhe‐jiang 315201 China

Laboratory of Molecular Imaging and Nanomedicine National Institute of Biomedical Imaging and Bioengineering National Institutes of Health Bethesda MD 20892 USA

Laboratory of Cellular Imaging and Macromolecular Biophysics National Institute of Biomedical Imaging and Bioengineering National Institutes of Health Bethesda MD 20892 USA

Key Laboratory of Applied Marine Biotechnology of Ministry of Education Ningbo University Ningbo 315211 China

Funding

Youth Innovation Promotion Association of the Chinese Academy of Sciences · National Natural Science Foundation of China · Zhejiang Province Public Welfare Technology Application Research Project · National Institute of Biomedical Imaging and Bioengineering · National Institutes of Health

References (41)

Show source-provided references
1. 10.1038/nnano.2013.6510.1038/nnano.2013.65 ↗
2. 10.1002/adma.20170101310.1002/adma.201701013 ↗
3. 10.1002/adma.20160438110.1002/adma.201604381 ↗
4. 10.1038/nnano.2016.7210.1038/nnano.2016.72 ↗
5. 10.1038/nmat387710.1038/nmat3877 ↗
6. 10.1038/nnano.2014.25410.1038/nnano.2014.254 ↗
7. 10.1038/ncomms1425410.1038/ncomms14254 ↗
8. 10.1038/ncomms1546810.1038/ncomms15468 ↗
9. 10.1016/j.acra.2012.05.01910.1016/j.acra.2012.05.019 ↗
10. 10.1002/adma.20170109510.1002/adma.201701095 ↗
11. 10.1038/nm146710.1038/nm1467 ↗
12. 10.1021/acs.molpharmaceut.6b0083910.1021/acs.molpharmaceut.6b00839 ↗
13. 10.1039/c3tb20648c10.1039/c3tb20648c ↗
14. 10.1002/smll.20150230910.1002/smll.201502309 ↗
15. 10.1016/j.biomaterials.2015.08.02210.1016/j.biomaterials.2015.08.022 ↗
16. 10.1016/j.colsurfb.2014.11.04510.1016/j.colsurfb.2014.11.045 ↗
17. 10.1002/adma.20160541610.1002/adma.201605416 ↗
18. 10.1021/acsnano.7b0492410.1021/acsnano.7b04924 ↗
19. 10.1007/s00330-004-2379-010.1007/s00330-004-2379-0 ↗
20. Akgun H. · Arch. Pathol. Lab. Med. · 2006 · 130 · 135410.5858/2006-130-1354-AGCMNA ↗
21. 10.1002/adma.20150427010.1002/adma.201504270 ↗
22. 10.1021/nn507193f10.1021/nn507193f ↗
23. 10.1021/ja104503g10.1021/ja104503g ↗
24. 10.1039/C6NR02620F10.1039/C6NR02620F ↗
25. 10.1016/j.biomaterials.2011.03.01810.1016/j.biomaterials.2011.03.018 ↗
26. 10.1002/adfm.20150286810.1002/adfm.201502868 ↗
27. 10.1186/1556-276X-7-46210.1186/1556-276X-7-462 ↗
28. 10.7150/thno.1613510.7150/thno.16135 ↗
29. 10.7150/thno.1324210.7150/thno.13242 ↗
30. 10.7150/thno.1031910.7150/thno.10319 ↗
31. 10.1021/nn502986e10.1021/nn502986e ↗
32. 10.1016/j.jconrel.2013.10.03810.1016/j.jconrel.2013.10.038 ↗
33. 10.1021/nn304837c10.1021/nn304837c ↗
34. 10.1021/acsnano.6b0768410.1021/acsnano.6b07684 ↗
35. 10.1021/nn305991e10.1021/nn305991e ↗
36. 10.1038/nnano.2006.17010.1038/nnano.2006.170 ↗
37. 10.1038/nmat390810.1038/nmat3908 ↗
38. 10.1038/nnano.2017.17010.1038/nnano.2017.170 ↗
39. Aronova M. A. · Mater. Res. Soc. Bull. · 2012 · 37 · 5310.1557/mrs.2011.329 ↗
40. 10.1021/nl301742h10.1021/nl301742h ↗
41. 10.1038/nchem.28210.1038/nchem.282 ↗